http://orcid.org/0000-0001-9420-6701
References
- Ma X. Epidemiology of myelodysplastic syndromes. Am J Med. 2012;125:S2–S5.
- Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 2004;101:2999–3004.
- Calin GA, Liu CG, Sevignani C, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA. 2004;101:11755–11760.
- Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 2005;102:13944–13949.
- Raaijmakers MH, Mukherjee S, Guo S, et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature. 2010;464:852–857.
- Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al. Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype. Nat Med. 2010;16:49–58.
- Song SJ, Ito K, Ala U, et al. The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell. 2013;13:87–101.
- Jung SW, Lee SY, Jekarl DW, et al. Cytogenetic characteristics and prognosis analysis in 231 myelodysplastic syndrome patients from a single institution. Leuk Res. 2011;35:735–740.
- Lee DS, Kim SH, Seo EJ, et al. Predominance of trisomy 1q in myelodysplastic syndromes in Korea: is there an ethnic difference? A 3-year multi-center study. Cancer Genet Cytogenet. 2002;132:97–101.
- Choi JS, Nam MH, Yoon SY, et al. MicroRNA-194-5p could serve as a diagnostic and prognostic biomarker in myelodysplastic syndromes. Leuk Res. 2015;39:763–768.
- Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–2465.
- Sutcliffe T, Fu L, Abraham J, et al. A functional wild-type p53 gene is expressed in human acute myeloid leukemia cell lines. Blood. 1998;92:2977–2979.
- Hoffman Y, Bublik DR, Pilpel Y, et al. miR-661 downregulates both mdm2 and mdm4 to activate p53. Cell Death Differ. 2014;21:302–309.
- Raza A, Alvi S, Broady-Robinson L, et al. Cell cycle kinetic studies in 68 patients with myelodysplastic syndromes following intravenous iodo- and/or bromodeoxyuridine. Exp Hematol. 1997;25:530–535.
- Greenberg PL. Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Leuk Res. 1998;22:1123–1136.
- Li Z, Liu YH, Diao HY, et al. MiR-661 inhibits glioma cell proliferation, migration and invasion by targeting hTERT. Biochem Biophys Res Commun. 2015;468:870–876.
- Reddy SD, Pakala SB, Ohshiro K, et al. MicroRNA-661, a c/EBPalpha target, inhibits metastatic tumor antigen 1 and regulates its functions. Cancer Res. 2009;69:5639–5642.
- Fan L, Zhu C, Qiu R, et al. MicroRNA-661 enhances TRAIL or STS induced osteosarcoma cell apoptosis by modulating the expression of cytochrome c1. Cell Physiol Biochem. 2017;41:1935–1946.
- Hussein K, Theophile K, Busche G, et al. Aberrant microRNA expression pattern in myelodysplastic bone marrow cells. Leuk Res. 2010;34:1169–1174.
- McCubrey JA, Lertpiriyapong K, Fitzgerald TL, et al. Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis. Adv Biol Regul. 2017;63:32–48.